NCT00002110已完成2 期
A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease
Mylan Laboratories12 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
- 试验地点
- 12
研究概览
简要总结
To determine the safety and tolerance of low-dose versus high-dose cysteamine administered concurrently with zidovudine (AZT). To determine the pharmacokinetics and effects on immune function and viral load in patients receiving these drug regimens.
详细描述
Patients receive high or low doses of cysteamine plus AZT or placebo plus AZT. The target dose of cysteamine is determined by titration of the dose over a 6-week period, after which the patient receives 24 additional weeks of treatment. An initial cohort of 36 patients will be enrolled in a 10-week pilot phase. Accrual will be temporarily suspended while data from the pilot phase is assessed.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Chemoprophylaxis for Pneumocystis carinii pneumonia, candidiasis, Mycobacterium tuberculosis, and herpes as prescribed by the investigator.
- •Recombinant erythropoietin and G-CSF if clinically indicated.
- •Patients must have:
- •Documented HIV infection.
- •CD4 count 300 - 500 cells/mm
- •Prior AZT therapy for at least 3 months but less than 12 months prior to study entry.
- •No past or current AIDS-defining opportunistic infection.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Kaposi's sarcoma requiring systemic therapy.
- •Active malignancy other than basal cell carcinoma or in situ cervical carcinoma.
- •Concurrent Medication:
- •Antiretroviral therapy other than AZT.
- •Immunosuppressive drugs.
- •Investigational HIV drugs/therapies other than study drug.
- •Interferon.
- •Steroids.
- •Hematopoietins.
- •Cytotoxic chemotherapy including Adriamycin, bleomycin, and vincristine.
- •Concurrent Treatment:
- •Radiation therapy.
- •Patients with the following prior condition are excluded:
- •History of treatment-limiting intolerance to 500-600 mg AZT daily as manifested by the same recurrent grade 3 toxicity or any prior grade 4 toxicity.
- •Prior Medication:
- •Prior antiretroviral therapy other than AZT.
- •AZT for at least 3 months but no more than 12 months prior to study entry.
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of DysuriaDysuriaNCT01657448EMS316
已完成
3 期
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.Chronic Hepatitis CNCT01178996sigma-tau i.f.r. S.p.A.552
已完成
2 期
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast CancerMetastatic Breast CancerNCT00364195YM BioSciences33
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Lymphoma, B-CellSmall Lymphocytic LymphomaWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaRichter's TransformationMarginal Zone LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaNCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190
已完成
1 期
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 CapsuleHealthy VolunteersNCT02034773Celgene Corporation64